Table 4.
Unadjusted yearly change in fat free mass index (FFMI) and fat mass index (FMI) for each baseline predictor variable, estimated bylinear mixed models
| Baseline variables | Yearly change in FFMI | p-value | Yearly change in FMI | p-value |
|---|---|---|---|---|
|
Sex |
|
|
|
|
| Women |
−0.0613 |
|
0.01599 |
|
| Men |
−0.0662 |
0.91 |
−0.04131 |
0.24 |
|
Age |
|
|
|
|
| at age 60 |
−0.0377 |
|
−0.0024 |
|
| per 10 yrs increase |
−0.0867 |
0.01 |
−0.0584 |
0.10 |
|
Smoking |
|
|
|
|
| Ex |
−0.0772 |
|
−0.0762 |
|
| Current |
−0.0477 |
0.49 |
0.0531 |
0.01 |
|
GOLD stage |
|
|
|
|
| II |
0.0024 |
|
0.0032 |
|
| III |
−0.1151 |
0.01 |
−0.0333 |
0.47 |
| IV |
−0.1861 |
0.01 |
−0.0921 |
0.27 |
|
FEV1 |
|
|
|
|
| at 50% of predicted |
−0.0624 |
|
−0.0197 |
|
| per 10% decrease in predicted value |
−0.0477 |
0.00 |
−0.0227 |
0.18 |
|
Hypoxemia |
|
|
|
|
| PaO2 > 9 kPa |
−0.0664 |
|
0.0006 |
|
| PaO2 8–9 kPa |
−0.0506 |
0.77 |
0.0270 |
0.65 |
| PaO2 < 8 kPa |
−0.1052 |
0.61 |
−0.2695 |
0.00 |
|
Exacerbations last year |
|
|
|
|
| 0-1 |
−0.0618 |
|
−0.0115 |
|
| 2+ |
−0.0764 |
0.81 |
−0.0638 |
0.43 |
|
Charlson Comorbidity Score |
|
|
|
|
| I |
−0.0768 |
|
0.0378 |
|
| II |
−0.0652 |
0.82 |
−0.0737 |
0.05 |
| III |
0.0333 |
0.11 |
−0.1616 |
0.01 |
| IV+ |
−0.1231 |
0.62 |
−0.0962 |
0.20 |
|
Cachexia |
|
|
|
|
| No |
−0.0495 |
|
−0.0255 |
|
| Yes |
−0.0983 |
0.31 |
−0.0089 |
0.76 |
|
Using inhaled steroids |
|
|
|
|
| No |
−0.0243 |
|
0.0610 |
|
| Yes |
−0.0828 |
0.20 |
−0.0574 |
0.02 |
|
Use of long-acting beta2 agonists |
|
|
|
|
| No |
−0.0101 |
|
0.0696 |
|
| Yes |
−0.0862 |
0.01 |
−0.0557 |
0.02 |
|
Use of theophyllin |
|
|
|
|
| No |
−0.0605 |
|
−0.0086 |
|
| Yes | −0.1097 | 0.54 | −0.1421 | 0.14 |